Our findings indicate that a serum IL-19 assay for disease activity could provide to clinicians managing psoriasis patients an important tool to complement the therapeutic advances being made in treating this chronic, immune-mediated, skin disease14. The gene discussed is IL19; the disease is psoriasis.